



# Pfizer Reports Second-Quarter 2008 Results

Tuesday, July 22, 2008 - 05:30pm

Pfizer Reaffirms Full-Year 2008 Revenue and Adjusted Diluted EPS(1) Guidance; On-Track to Achieve Total Cost-Reduction Target Second-Quarter 2008 Revenues of \$12.1 Billion Compared with \$11.1 Billion in the Year-Ago Quarter Second-Quarter 2008 Reported Diluted EPS of \$0.41 Compared with \$0.18 in the Year-Ago Quarter Second-Quarter 2008 Adjusted Diluted EPS(1) of \$0.55 Compared with \$0.42 in the Year-Ago Quarter Second-Quarter 2008 Adjusted Total Costs(2) Decreased by \$475 Million Compared with the Year-Ago Quarter Excluding Foreign Exchange

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE):

(\$ in millions, except per share amounts)

	2008	2007	Change	2008	2007	Change	Second-Quarter Reported Revenues	Year-to-Date
Revenues	\$ 12,129	\$ 11,084	9%	\$ 23,977	\$ 23,558	2%		
Net Income	2,776	1,267	119%	5,560	4,659	19%		
Diluted EPS	0.41	0.18	128%	0.82	0.66	24%		
Adjusted Income(1)	3,698	2,944	26%	7,797	7,748	1%		
Adjusted Diluted EPS(1)	0.55	0.42	31%	1.15	1.10	5%		

See end of text prior to tables for notes.

Pfizer Inc (NYSE: PFE) today reported financial results for the second-quarter 2008. The Company recorded revenues of \$12.1 billion, an increase of 9% compared with \$11.1

billion in the year-ago quarter. In the U.S., revenues were \$4.8 billion, a decrease of 2%, while international revenues were \$7.4 billion, an increase of 18%. Revenues reflect the positive impact of foreign exchange, which increased revenues by approximately \$800 million or 7%, as well as the solid performance of many key products. These factors more than offset the revenue declines due to the loss of U.S. exclusivity for Zyrtec, which Pfizer ceased selling in late January 2008, and for Camptosar in February 2008. Zyrtec and Camptosar second-quarter 2008 revenues decreased by \$377 million and \$104 million, respectively, compared with the year-ago quarter.

For the second-quarter 2008, Pfizer posted reported net income of \$2.8 billion, an increase of 119% compared with \$1.3 billion in the prior-year quarter, and reported diluted EPS of \$0.41, an increase of 128% compared with \$0.18 in the prior-year quarter. These increases were primarily attributable to lower restructuring charges from cost-reduction initiatives, as well as savings generated by those initiatives, the positive impact of foreign exchange and favorable income tax adjustments; these positive factors were partially offset by increased in-process research and development expenses associated with the acquisitions of Serenex, Inc. and Encysive Pharmaceuticals Inc., which closed in the second-quarter 2008.

For the first-half 2008, Pfizer recorded revenues of \$24.0 billion, an increase of 2% compared with \$23.6 billion in the same period in 2007, despite the loss of U.S. exclusivity of Norvasc (March 2007), Zyrtec (January 2008) and Camptosar (February 2008), which collectively decreased revenues by \$1.4 billion during the first-half 2008. The 2% increase reflects the favorable impact of foreign exchange, which increased revenues by approximately \$1.4 billion or 6%, in addition to the solid performance of many key products. In the U.S., revenues were \$10.3 billion, a decrease of 12%, while international revenues were \$13.7 billion, an increase of 15%.

For the first-half 2008, the Company posted reported net income of \$5.6 billion, an increase of 19% compared with \$4.7 billion in the prior-year period, and reported diluted EPS of \$0.82, an increase of 24% compared with \$0.66 in the prior-year period. These increases were primarily attributable to the favorable impact of foreign exchange and lower restructuring charges associated with cost-reduction initiatives, mainly employee-related costs, as well as the savings generated by those initiatives.

### **Adjusted Income(1) and Adjusted Diluted EPS(1) Results**

For the second-quarter 2008, Pfizer posted adjusted income(1) of \$3.7 billion, an increase of 26% compared with \$2.9 billion in the year-ago quarter, and adjusted diluted EPS(1) of

\$0.55, an increase of 31% compared with \$0.42 in the year-ago quarter. For the first-half 2008, Pfizer posted adjusted income(1) of \$7.8 billion, an increase of 1% compared with \$7.7 billion in the first-half 2007, and adjusted diluted EPS(1) of \$1.15, an increase of 5% compared with \$1.10 in the first-half 2007. In both periods, adjusted income(1) and adjusted diluted EPS(1) reflect the positive impact of foreign exchange, the non-recurrence of the one-time 2007 payment to Bristol-Myers Squibb Company in connection with our collaboration to develop and commercialize apixaban, favorable income tax adjustments as well as the savings associated with cost-reduction initiatives.

Reported and adjusted diluted EPS(1) were also positively impacted by the full benefit of Pfizer's purchase of \$10.0 billion of the Company's common stock in 2007.

## **Executive Commentary**

"We are pleased with the financial results we delivered this quarter, which were driven in part by the solid performance in our Pharmaceutical and Animal Health businesses," stated Chairman and Chief Executive Officer Jeff Kindler. "Many of our key products continued to perform well both in the U.S. and international markets, including Lyrica, Celebrex, Viagra and Geodon, as well as Lipitor in the face of a highly competitive statin market. The benefit of our broad-based portfolio of products, our geographic reach and our diverse strategies for growth was evident in this quarter's financial results, which clearly demonstrate our ability to continue to deliver solid performance in an increasingly challenging environment."

"During the quarter, we entered into an important agreement with Ranbaxy Laboratories Ltd. that provided substantial certainty to patients and our shareholders regarding the availability of a generic version of Lipitor in the U.S. after November 30, 2011. We are pleased with the resolution of this issue with Ranbaxy, as it reaffirms the value and importance of intellectual property for Pfizer and the pharmaceutical industry as a whole," continued Kindler.

Frank D'Amelio, Chief Financial Officer, commented, "Based on our year-to-date performance and outlook for the remainder of 2008, we are reaffirming our full-year 2008 revenue and adjusted diluted EPS(1) guidance as well as our plan to reduce absolute adjusted total costs(2) by at least \$1.5 to \$2.0 billion at the end of 2008 compared with 2006 on a constant currency basis(3). We expect the remainder of this reduction to gain momentum throughout the second half of the year, with much of the remaining savings to be realized in the fourth quarter."

“Given the continued strength of our balance sheet and significant operating cash flow, we remain confident that we have the financial wherewithal to successfully execute our strategies and continue to meet our financial objectives,” D’Amelio continued. “During the second quarter, we repurchased approximately \$500 million, or 26.4 million shares, of our common stock.”

<b>Product Performance (\$ in millions, except percentages)</b>			<b>Second-Quarter</b>			
<b>First-Half</b>	2008	2007	Change	2008	2007	Change
				In-Line Products(4)	\$ 9,840	\$ 8,486
16 %	\$ 19,442	\$ 18,040	8 %	New Products(5)	441	351
49 %				Total In-Line and New Products(6)	10,281	8,837
18,659	9 %			Loss of Exclusivity Products(7)		772

772

1,268

1,594

3,027

(47

%)

(39 %) Total Pharmaceutical 11,053 10,105 9 % 21,957 21,686

1 % Animal Health 715 632 13 % 1,334 1,218 10 % Other(8)

361 347 4 % 686 654 5 % Total Revenues \$ 12,129 \$ 11,084

9 % \$ 23,977 \$ 23,558 2 %

See end of text prior to tables for notes.

## Pharmaceutical

Pharmaceutical revenues for the second-quarter 2008 were \$11.1 billion, an increase of 9% compared with the prior-year quarter, including the favorable impact of foreign exchange, which increased revenues by approximately \$730 million or 7%. Second-quarter 2008 revenues from in-line and new products(6) increased 16% compared with the year-ago quarter; this excludes the impact of the loss of U.S. exclusivity of Norvasc,

Zyrtec and Camptosar, which collectively resulted in a revenue decline of \$496 million or 39% compared with the year-ago quarter.

Lipitor revenues in the second-quarter 2008 were \$3.0 billion, an increase of 9% compared with the prior-year quarter, reflecting the favorable impact of foreign exchange, which increased revenues by approximately \$170 million or 6%. In the U.S., Lipitor revenues increased 1% compared with the prior-year quarter, while revenues from international markets rose 18%, due to the favorable impact of foreign exchange of 13% and operational growth of 5%. The global statin market continues to be highly competitive, with both branded and generic competition in an increasingly cost-sensitive environment. Pfizer continues to respond to these market dynamics with an integrated, multi-channel effort, emphasizing Lipitor's strong clinical profile demonstrated in over 400 completed or ongoing clinical trials including more than 80,000 patients and in more than 151 million patient years of experience over 15 years.

Lyrica revenues in the second-quarter 2008 were \$614 million, an increase of 52% compared with the prior-year quarter, driven by strong efficacy and high patient and physician satisfaction in managing nerve pain associated with diabetes and nerve pain after shingles, the June 2007 U.S. approval for the management of fibromyalgia, a branded and unbranded advertising strategy focused on increasing both Lyrica and fibromyalgia awareness as well as the favorable impact of foreign exchange. In the U.S., Lyrica revenues rose to \$335 million, an increase of 55% compared to the prior-year quarter, while international revenues grew to \$279 million, an increase of 48%.

Celebrex revenues in the second-quarter 2008 were \$589 million, an increase of 23% compared with the year-ago quarter, primarily driven by the continued educational and promotional efforts supporting the risk-benefit proposition of this medicine, as well as the favorable impact of foreign exchange. In the U.S., Celebrex revenues rose to \$416 million, an increase of 22% compared with the prior-year quarter, while international revenues grew to \$173 million, an increase of 27%.

Sutent revenues in the second-quarter 2008 continued to demonstrate strong performance and market leadership in its approved indications, advanced renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST), with revenues of \$211 million, an increase of 45% compared with the year-ago quarter. In the U.S., Sutent revenues were \$60 million, a decrease of 2% compared with the prior-year quarter, while international revenues grew to \$151 million, an increase of 80%. To date, Sutent has launched in 61 countries, with four in the second-quarter 2008 including Japan, China and Russia, and six planned in the next 12 months. As part of Pfizer's robust life cycle plan,

clinical trials continue for potential additional indications where Sutent shows promise and where there is a need for additional treatments, most notably breast, colorectal and lung cancers.

Chantix (known as Champix outside the U.S.) revenues in the second-quarter 2008 were \$207 million, an increase of 3% compared with the second-quarter 2007. In the U.S., Chantix revenues declined to \$109 million, a decrease of 35% compared with the prior-year quarter, while international revenues grew to \$98 million, an increase of 197%. U.S. results were negatively impacted by the recent updates to the Chantix U.S. label to include additional safety information, as well as certain external events relating to Chantix. Pfizer continues its educational and promotional efforts focused on the Chantix risk-benefit proposition, the significant health consequences of smoking and the importance of the physician-patient dialogue to help patients effectively use Chantix to reach their health goal of becoming smoke free. Since its approval in the U.S. in May 2006, Chantix/Champix has been approved in 76 countries and has been used by more than six million patients, an increasing number of whom are covered by third-party payers. In the second-quarter 2008, Champix launched in Japan, which has more than 30 million smokers, as well as Malaysia and Singapore, with nine launches planned in the next 12 months, including Russia, Turkey and China.

## **Animal Health**

Animal Health revenues for the second-quarter 2008 were \$715 million, an increase of 13% compared with \$632 million in the year-ago quarter. The increase was driven by the favorable impact of foreign exchange, which increased revenues by approximately \$50 million or 8%, in addition to strong global livestock and companion animal product performance.

## **Costs and Expenses**

In the second-quarter 2008, adjusted cost of sales(1) as a percentage of revenues was 16.9% compared with 17.0% in the second-quarter 2007. This reflects the impact of foreign exchange on cost of sales in addition to unfavorable changes in geographic mix, which were slightly more than offset by the favorable effect of our cost-reduction initiatives.

Adjusted selling, informational and administrative (SI&A) expenses(1) were \$3.7 billion in the second-quarter 2008, a decrease of 1% compared with the prior-year quarter. The favorable impact of our cost-reduction initiatives was partially offset by the unfavorable impact of foreign exchange on expenses compared with the year-ago period.

Adjusted research and development (R&D) expenses(1) were \$1.9 billion in the second-quarter 2008, a decrease of 8% compared with the year-ago quarter, due primarily to the non-recurrence of the one-time 2007 payment to Bristol-Myers Squibb Company in connection with our collaboration to develop and commercialize apixaban in addition to the realization of savings associated with our cost-reduction initiatives.

Overall, foreign exchange increased adjusted total costs(2) by approximately \$440 million or 6% in the second-quarter 2008 compared with the prior-year period. Excluding the impact of foreign exchange, our adjusted total costs(2) decreased by \$475 million or 6% compared with the year-ago quarter. The operational improvement was driven primarily by the reduction in overall workforce level to 84,500 at the end of second-quarter 2008, a reduction of 13,500 over the past 18 months. Manufacturing and research and development site exits have also contributed to the operational improvement.

Pfizer continues to make progress on its target to reduce absolute adjusted total costs(2) by at least \$1.5 to \$2.0 billion at the end of 2008 compared with 2006 on a constant currency basis(3). These initiatives span essentially all divisions, functions, markets and sites. As of the end of second-quarter 2008, Pfizer had achieved \$1.2 billion of the target. The Company expects to achieve much of the remaining reduction in the fourth-quarter 2008, which will favorably impact fourth-quarter earnings.

## Financial Guidance

For the full-year 2008, Pfizer's financial guidance, at current exchange rates(9) is summarized below. The guidance on adjusted cost of sales(1) as a percentage of revenue has been tightened to 15.0% - 15.5% from 14.5% - 15.5%. Additionally, guidance on the range for the effective tax rate on adjusted income(1) has been reduced to 21.5% - 22.0% from 22.0% - 22.5%.

	<b>2007 Actual</b>	<b>2008 Guidance</b>
Revenues	\$48.2 billion	\$47.0 to \$49.0 billion
Adjusted Cost of Sales(1) as a Percentage of Revenues		

16.0%

15.0% to 15.5%

Adjusted SI&A Expenses(1)	\$15.2 billion	\$14.4 to \$14.9 billion	Adjusted R&D Expenses(1)	\$7.5 billion	\$7.3 to \$7.6 billion
Effective Tax Rate on Adjusted Income(1)	21.0%	21.5% to 22.0%	Reported Diluted EPS(10)	\$1.17	\$1.73 to \$1.88

Diluted EPS(1) \$2.18 \$2.35 to \$2.45 Cash Flows from Operations \$13.4 billion \$17.0 to \$18.0 billion

**For additional details, please see the attached financial schedules, product revenue tables, supplemental information and disclosure notice.**

(1) "Adjusted income" and its components and "adjusted diluted earnings per share (EPS)" are defined as reported net income and its components and reported diluted EPS excluding purchase-accounting adjustments, acquisition-related costs, discontinued operations and certain significant items. Adjusted Cost of Sales, Adjusted SI&A expenses and Adjusted R&D expenses are income statement line items prepared on the same basis, and therefore, components of the overall Adjusted Income measure. As described under *Adjusted Income* in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of Pfizer's Form 10-Q for the fiscal quarter ended March 30, 2008, management uses adjusted income, among other factors, to set performance goals and to measure the performance of the overall company. We believe that investors' understanding of our performance is enhanced by disclosing this measure. Reconciliations of second-quarter 2008 and 2007, first-half 2008 and 2007, and full-year 2007 adjusted income and its components and adjusted diluted EPS to reported net income and its components and reported diluted EPS, as well as reconciliations of full-year 2008 adjusted income and adjusted diluted EPS guidance to full-year 2008 reported net income and reported diluted EPS guidance, are provided in the materials accompanying this report. The adjusted income and its components and adjusted diluted EPS measures are not, and should not be viewed as, substitutes for U.S. GAAP net income and diluted EPS.

(2) Represents primarily the total of Adjusted Cost of Sales(1), Adjusted SI&A expenses(1) and Adjusted R&D expenses(1).

(3) Constant currency basis means that the applicable projected financial measure is based upon the actual foreign exchange rates in effect during 2006.

(4) Represents worldwide revenues for all pharmaceutical products, excluding revenues included in notes (5) and (7).

(5) Represents worldwide revenues for pharmaceutical products launched since 2006: Chantix/Champix, Eraxis, Selzentry/Celsentri, Sutent and Thelin.

(6) Total worldwide pharmaceutical revenues excluding the revenues of major products that have lost exclusivity in the U.S. in 2007 and 2008 as described in note (7). See the



table accompanying this report.

(7) Represents worldwide revenues for pharmaceutical products that lost exclusivity in the U.S. in 2007 and 2008: Camptosar, Norvasc and Zyrtec.

(8) Includes Consumer Healthcare business transition activity, Capsugel and Pfizer Centersource.

(9) Current exchange rates approximate rates at the time of the second-quarter earnings press release (July 2008).

(10) Excludes the charges associated with business development transactions not completed as of June 29, 2008.

PFIZER INC AND SUBSIDIARY COMPANIES CONSOLIDATED  
STATEMENTS OF INCOME (UNAUDITED)  
(millions of dollars, except per common share data)

Second Quarter

% Incr./ (Decr.)

Six Months

% Incr./ (Decr.)

2008	2007	2008	2007	Revenues	\$ 12,129	\$ 11,084	9	\$ 23,977	\$ 23,558														
2				Costs and expenses:		Cost of sales (a)	2,289	2,109	9														
4,275	3,996	7		Selling, informational and administrative expenses (a)				3,863															
3,844	1	7,355	7,205	2				Research and development expenses (a)	1,966														
2,165	(9)	3,757	3,830	(2)				Amortization of intangible assets	663	783													
(15)	1,442	1,598	(10)					Acquisition-related in-process research and development charges	156	-	*	554	283	95			Restructuring charges and acquisition-related costs	569	1,051	(46)	747	1,863	(60)

Other (income)/ deductions--net

(167 ) (487 ) (66 ) (500 ) (889 ) (44 )

Income from continuing operations before provision for taxes on income and minority interests

2,790	1,619	72	6,347	5,672	12	Provision for taxes on income	25				
272	(91 )	788	961	(18 )	Minority interests	6	2	243	12	5	149
Income from continuing operations		2,759	1,345	105	5,547	4,706	18				
Discontinued operations:						Income/(loss) from discontinued					
operations--net of tax (1 ) - *						(5 ) - * Gains/(losses) on sales of					
discontinued operations--net of tax 18 (78 ) *						18 (47 ) * Discontinued					
operations--net of tax 17 (78 ) *						13 (47 ) * Net income \$ 2,776 \$ 1,267					
119	\$ 5,560	\$ 4,659	19	Earnings per common share - basic:							
Income from continuing operations		\$ 0.41	\$ 0.19	116	\$ 0.82	\$ 0.67	22				
Discontinued operations--net of tax		-	(0.01 ) *	0.01	(0.01 ) *	Net income \$					
0.41	\$ 0.18	128	\$ 0.83	\$ 0.66	26	Earnings per common share - diluted:					
Income from continuing operations		\$ 0.41	\$ 0.19	116	\$ 0.82	\$					
0.67	22	Discontinued operations--net of tax		-	(0.01 ) *	-	(0.01 ) *	Net			
income \$ 0.41		\$ 0.18	128	\$ 0.82	\$ 0.66	24	Weighted-average shares used				
to calculate earnings per common share:						Basic 6,732 6,966					
6,736	7,009	Diluted		6,748	6,990	6,754	7,033				

(a) Exclusive of amortization of intangible assets, except as discussed in footnote 4 below.

\* Calculation not meaningful.

Certain amounts and percentages may reflect rounding adjustments.

1.

The above financial statements present the three-month and six-month periods ended June 29, 2008 and July 1, 2007. Subsidiaries operating outside the United States are included for the three-month and six-month periods ended May 25, 2008 and May 27, 2007.

2. The financial results for the three-month and six-month periods ended June 29, 2008 are not necessarily indicative of the results which ultimately might be achieved for the current year. 3. As required, the estimated value of *Acquisition-related in-process research and development charges* (IPR&D) is expensed at acquisition date. In the

second quarter of 2008, we expensed \$156 million of IPR&D, primarily related to our acquisitions of Serenex, Inc. and Encysive Pharmaceuticals Inc. In the first quarter of 2008, we expensed \$398 million of IPR&D, primarily related to our acquisitions of CovX, Coley Pharmaceutical Group, Inc. and two smaller acquisitions related to Animal Health. In the first quarter of 2007, we expensed \$283 million of IPR&D, primarily related to our acquisitions of BioRexis Pharmaceutical Corp. and Embrex, Inc. 4. Amortization expense related to acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute our products are included in *Amortization of intangible assets* as they benefit multiple business functions. Amortization expense related to acquired intangible assets that are associated with a single function are included in *Cost of sales, Selling, informational and administrative expenses* or *Research and development expenses*, as appropriate. 5. *Provision for taxes on income* includes tax benefits in the second quarter of 2008 of approximately \$305 million related to favorable tax settlements and of approximately \$426 million related to the sale of one of our biopharmaceutical companies (Esperion Therapeutics Inc.).

PFIZER INC AND SUBSIDIARY COMPANIES RECONCILIATION OF REPORTED NET INCOME AND ITS COMPONENTS AND REPORTED DILUTED EPS TO ADJUSTED INCOME AND ITS COMPONENTS AND ADJUSTED DILUTED EPS (UNAUDITED) (millions of dollars, except per common share data) Quarter Ended June

29, 2008 Reported

PurchaseAccountingAdjust-ments

Acqui-sition-RelatedCosts

Discon-tinuedOper-ations

CertainSigni-ficantItems(2)

Adjusted Revenues	\$ 12,129	\$ -	\$ -	\$ -	\$ (54 )	\$ 12,075	Costs and
expenses:							
		Cost of sales (a)	2,289	-	-	-	(253 )
2,036	Selling, informational and administrative expenses (a)	3,863	3	-	-	-	
(170 )	3,696	Research and development expenses (a)	1,966	(7 )	-	-	(90 )
)	1,869	Amortization of intangible assets	663	(628 )	-	-	35
Acquisition-related in-process R&D charges	156	(156 )	-	-	-	-	

Restructuring charges and acquisition-related costs 569 - (7) - (562) -  
 Other (income)/ deductions--net

(167) - - - (23) (190)

Income from continuing operations before provision for taxes on income and minority interests

2,790	788	7	-	1,044	4,629	Provision for taxes on income	25
184	2	-	714	925	Minority interests	6	- - - - 6
Income from continuing operations		2,759	604	5	-	330	3,698
Discontinued operations:		Income/(loss) from discontinued operations--net of tax					
(1)	-	-	1	-	-	Gains/(losses) on sales of discontinued operations--net of tax	
18	-	-	(18)	-	-	Discontinued operations--net of tax 17 - -	
(17)	-	-	Net income \$ 2,776		\$ 604	\$ 5	\$ (17) \$ 330 \$ 3,698

Earnings per common share - diluted:					Income from continuing				
operations	\$ 0.41	\$ 0.09	\$ -	\$ -	\$ 0.05	\$ 0.55	Discontinued operations--net		
of tax	-	-	-	-	-	Net income \$ 0.41 \$ 0.09 \$ - \$ - \$ 0.05 \$			
0.55	Six Months Ended June 29, 2008								

Reported

Purchase Accounting Adjust-ments

Acqui-sition-Related Costs

Discon-tinued Oper-ations

Certain Signi-ficant Items(2)

Adjusted Revenues	\$ 23,977	\$ -	\$ -	\$ -	\$ (106)	\$ 23,871	Costs and			
expenses:	Cost of sales (a)						4,275	-	-	(439)
3,836	Selling, informational and administrative expenses (a)	7,355	6	-	-					
(256)	7,105	Research and development expenses (a)	3,757	(14)	-					
(236)	3,507	Amortization of intangible assets	1,442	(1,380)	-					
62	Acquisition-related in-process R&D charges	554	(554)	-	-					
Restructuring charges and acquisition-related costs		747	-	(8)	-	(739)				
Other (income)/ deductions--net										

(500) (2) - - (21) (523)







\$

0.01 -

- Net income \$ 0.66 \$ 0.21

\$

- \$ 0.01 \$ 0.22 \$ 1.10

(a) Exclusive of amortization of intangible assets, except as discussed in note 1.

See end of tables for notes. Certain amounts may reflect rounding adjustments. Certain prior period amounts were reclassified to conform to the current period presentation.

PFIZER INC AND SUBSIDIARY COMPANIES NOTES TO RECONCILIATION OF REPORTED NET INCOME AND ITS COMPONENTS AND REPORTED DILUTED EPS TO ADJUSTED INCOME AND ITS COMPONENTS AND ADJUSTED DILUTED EPS (UNAUDITED)

1) Amortization expense related to acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute our products are included in *Amortization of intangible assets* as they benefit multiple business functions. Amortization expense related to acquired intangible assets that are associated with a single function are included in *Cost of sales, Selling, informational and administrative expenses* or *Research and development expenses*, as appropriate. 2) *Certain significant items* includes the following:

	Second Quarter		Six Months		(millions of dollars)					2008	2007	
	2008	2007			Restructuring charges - <i>Cost-reduction initiatives</i> (a)							
	\$ 562	\$ 1,035	\$ 739	\$ 1,830	Implementation costs - <i>Cost-reduction initiatives</i>							
	(b)	405	317	762	491	Consumer Healthcare business transition						
	activity(c)	(9)	(7)	(12)	(16)	Other	86	32	96	51	Total	
	certain significant items, pre-tax					1,044	1,377	1,585	2,356		Income	
	taxes(d)	(714)	(380)	(879)	(762)							

Total certain significant items--net of tax

\$ 330 \$ 997 \$ 706 \$ 1,594 (a) Included in *Restructuring charges and acquisition-related costs*. (b) Included in *Cost of sales* (\$210 million), *Selling, informational and administrative expenses* (\$100 million), *Research and development expenses* (\$94 million), and *Other (income)/deductions - net* (\$1 million) for the three months ended June 29, 2008. Included in *Cost of sales* (\$348 million), *Selling, informational and administrative expenses* (\$175 million), *Research and development expenses* (\$240 million), and *Other (income)/deductions - net* (\$1 million income) for the



six months ended June 29, 2008. Included in *Cost of sales* (\$170 million), *Selling, informational and administrative expenses* (\$79 million), *Research and development expenses* (\$131 million), and *Other (income)/deductions - net* (\$63 million income) for the three months ended July 1, 2007. Included in *Cost of sales* (\$264 million), *Selling, informational and administrative expenses* (\$128 million), *Research and development expenses* (\$162 million), and *Other (income)/deductions - net* (\$63 million income) for the six months ended July 1, 2007.

(c) Included in *Revenues* (\$54 million) and *Cost of sales* (\$45 million) for the three months ended June 29, 2008. Included in *Revenues* (\$106 million), *Cost of sales* (\$93 million) and *Selling, informational and administrative expenses* (\$1 million) for the six months ended June 29, 2008. Included in *Revenues* (\$51 million), *Cost of sales* (\$45 million), *Selling, informational and administrative expenses* (\$5 million), and *Other (income)/deductions - net* (\$6 million income) for the three months ended July 1, 2007. Included in *Revenues* (\$94 million), *Cost of sales* (\$80 million), *Selling, informational and administrative expenses* (\$7 million), and *Other (income)/deductions - net* (\$9 million income) for the six months ended July 1, 2007.

(d) Included in *Provision for taxes on income* and includes approximately \$426 million in the second quarter of 2008 related to the sale of one of our biopharmaceutical companies (Esperion Therapeutics Inc.).

PFIZER INC AND SUBSIDIARY COMPANIES RECONCILIATION OF REPORTED NET INCOME AND ITS COMPONENTS AND REPORTED DILUTED EPS TO ADJUSTED INCOME AND ITS COMPONENTS AND ADJUSTED DILUTED EPS (UNAUDITED) (millions of dollars, except per common share data) Twelve Months Ended  
December 31, 2007



1.17 \$ 0.37 \$ - \$ 0.01 \$ 0.63 \$ 2.18 (a)

Amortization expense related to acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute our products are included in *Amortization of intangible assets* as they benefit multiple business functions.

Amortization expense related to acquired intangible assets that are associated with a single function are included in *Cost of sales, Selling, informational and administrative expenses* or *Research and development expenses*, as appropriate.

Certain amounts may reflect rounding adjustments. Certain prior period amounts were reclassified to conform to the current period presentation.

**PFIZER INC SEGMENT/PRODUCT REVENUES SECOND QUARTER 2008  
(UNAUDITED) (millions of dollars) QUARTER-TO-DATE WORLDWIDE U.S.  
INTERNATIONAL % % % 2008 2007 Change 2008 2007  
Change 2008 2007 Change**

**TOTAL**

**REVENUES**

**12,129 11,084 9 4,766 4,841 (2) 7,363 6,243 18**

**PHARMA-**

**CEUTICAL**

**11,053 10,105 9 4,382 4,467 (2) 6,671 5,638 18**

**- CARDIO-**

**VASCULAR**

**AND**

**METABOLIC**

**DISEASES**

**4,467 4,083 9 1,788 1,740 3 2,679 2,343 14** LIPITOR 2,976 2,719 9  
1,397 1,384 1 1,579 1,335 18 NORVASC 627 642 (2) 42 18 132 585  
624 (6)

CHANTIX /

CHAMPIX

207 200 3 109 168 (35) 98 32 197 CADUET 146 119 22 116 109 7  
30 10 179 CARDURA 132 125 5 1 - 144 131 125 5

**- CENTRAL**

**NERVOUS**

**SYSTEM**

**DISORDERS**

**1,484 1,174 26 669 496 35 815 678 20** LYRICA 614 405 52 335  
218 55 279 187 48

GEODON /

ZELDOX

232 178 30 184 142 29 48 36 34 ZOLOFT 151 127 20 42 33 27  
109 94 17 ARICEPT\* 121 100 22 - - 29 121 100 22 NEURONTIN 104  
105 (1) 20 13 50 84 92 (8)

XANAX /

XANAX XR

90 79 15 15 13 23 75 66 13 RELPAX 80 66 21 48 39 23 32 27  
18

**- ARTHRITIS**

**AND PAIN**

**756 626 21 450 373 20 306 253 21** CELEBREX 589 478 23 416  
341 22 173 137 27

**- INFECTIOUS**

**AND**

**RESPIRATORY**

## DISEASES

**1,000 837 20 299 231 29 701 606 16** ZYVOX 292 202 45 170 118  
43 122 84 46 VFEND 187 145 29 55 42 33 132 103 28

ZITHROMAX /

ZMAX

109 108 1 1 5 (76) 108 103 4 DIFLUCAN 98 104 (6) 1 3 (48) 97  
101 (5) - **UROLOGY 765 663 15 384 323 19 381 340 12** VIAGRA 463  
382 21 199 142 41 264 240 9

DETROL /

DETROL LA

290 269 8 184 178 3 106 91 18 - **ONCOLOGY 650 652 - 109 239**  
**(55) 541 413 31** SUTENT 211 146 45 60 61 (2) 151 85 80  
CAMPTOSAR 137 241 (43) 6 130 (96) 131 111 19 AROMASIN 117 92 26  
32 28 17 85 64 29

- **OPHTHAL-**

**MOLOGY**

**444 400 11 119 123 (3) 325 277 17**

XALATAN /

XALACOM

436 389 12 119 123 (3) 317 266 19

- **ENDOCRINE**

**DISORDERS**

**305 253 20 67 57 19 238 196 20** GENOTROPIN 238 202 17 61 53  
17 177 149 17 - **ALL OTHER 619 1,025 (40) 181 665 (73) 438 360**  
**22**

ZYRTEC /

ZYRTEC D

8 385 (98 ) 8 385 (98 ) - - -

- **ALLIANCE**

**REVENUE**

(Aricept,

Exforge,

Macugen,

Mirapex,

Olmetec,

Rebif and

Spiriva)

563 392 44 316 220 44 247 172 42

**ANIMAL**

**HEALTH**

715 632 13 269 254 6 446 378 18 OTHER \*\* 361 347 4 115 120

(4 ) 246 227 8 \* - Represents direct sales under license agreement with Eisai Co., Ltd. \*\* - Includes Consumer Healthcare business transition activity, Capsugel and Pfizer Centersource. Certain amounts and percentages may reflect rounding adjustments.

**PFIZER INC SEGMENT/PRODUCT REVENUES SIX MONTHS 2008 (UNAUDITED)**

(millions of dollars) **YEAR-TO-DATE WORLDWIDE U.S. INTERNATIONAL**  
**% % % 2008 2007 Change 2008 2007 Change 2008 2007**  
**Change**

**TOTAL**

**REVE-**

**NUES**

**23,977 23,558 2 10,277 11,691 (12) 13,700 11,867 15**

**PHARMA-**

**CEUTICAL**

**21,957 21,686 1 9,523 10,935 (13) 12,434 10,751 16**

**- CARD-**

**IOVAS-**

**CULAR**

**AND**

**META-**

**BOLIC**

**DISEASES**

**8,961 9,238 (3) 3,928 4,764 (18) 5,033 4,474 13 LIPITOR 6,113 6,077**  
**1 3,148 3,521 (11) 2,965 2,556 16 NORVASC 1,140 1,711 (33) 37 529**  
**(93) 1,103 1,182 (7)**

**CHANTIX /**

**CHAMPIX**

**484 362 33 302 313 (3) 182 49 264 CADUET 293 265 11 236 244 (3**  
**) 57 21 169 CARDURA 253 259 (2) 3 2 39 250 257 (3)**

**- CEN-**

**TRAL**

**NERVOUS**

**SYSTEM**

**DIS-**

**ORDERS**

**2,870 2,419 19 1,353 1,133 19 1,517 1,286 18** LYRICA 1,196 800 50  
686 459 50 510 341 49

GEODON /

ZELDOX

473 394 20 384 324 18 89 70 28 ZOLOFT 273 273 - 68 101 (33 )  
205 172 19 ARICEPT\* 225 185 22 - - 47 225 185 22  
NEUR-

ONTIN

193 215 (10 ) 33 36 (8 ) 160 179 (10 )  
XANAX /

XANAX XR

176 154 14 32 28 14 144 126 15 RELPAX 157 149 6 97 96 1 60  
53 13  
**- ARTH-**

**RITIS**

**AND PAIN**

**1,511 1,375 10 954 896 6 557 479 16** CELEBREX 1,200 1,076 12  
880 817 8 320 259 24

**- INFEC-**

**TIOUS**

**AND**

**RESPIR-**

**ATORY**

**DISEASES**

**1,931 1,750 10 598 566 6 1,333 1,184 13** ZYVOX 551 460 20 334



301 11 217 159 37 VFEND 358 293 22 108 101 7 250 192 30  
ZITHRO-

MAX /

ZMAX

229 239 (4) 7 18 (63) 222 221 1 DIFLUCAN 187 215 (13) 4 6 (31)  
183 209 (13)

- UROL-

**OGY**

**1,549 1,414 10 831 776 7 718 638 13** VIAGRA 923 816 13 422  
366 15 501 450 11

DETROL /

DETROL LA

603 572 5 406 401 1 197 171 16

- ONCO-

**LOGY**

**1,287 1,247 3 306 483 (37) 981 764 28** SUTENT 401 248 62 126  
114 10 275 134 106

CAMPTO-

SAR

329 470 (30) 89 260 (66) 240 210 15 AROMASIN 221 185 19 69 63  
10 152 122 24

- OPHTH-

**ALMO-**

**LOGY**

**857 766 12 254 249 2 603 517 17**

XALATAN /

XALACOM

841 749 12 254 249 2 587 500 17

**- ENDO-**

**CRINE**

**DIS-**

**ORDERS**

**563 498 13 129 121 7 434 377 15**

GENO-

TROPIN

444 403 10 116 113 3 328 290 13 **- ALL OTHER 1,377 2,189 (37 )**

**562 1,484 (62 ) 815 705 16**

ZYRTEC /

ZYRTEC D

125 846 (85 ) 125 846 (85 ) - - -

**- ALLI-**

**ANCE**

**REVENUE**

**(Ari-**

**cept,**

**Exforge,**

**Macugen,**

**Mirapex,**

**Olmetec,**

**Rebif and**

**Spiriva)**

**1,051 790 33 608 463 31 443 327 35**

**ANIMALHEALTH**

**1,334 1,218 10 509 518 (2) 825 700 18 OTHER \*\* 686 654 5 245**

**238 3 441 416 6 \* - Represents direct sales under license agreement  
with Eisai Co., Ltd. \*\* - Includes Consumer Healthcare business**

**transition activity, Capsugel and Pfizer Centersource. Certain amounts  
and percentages may reflect rounding adjustments.**

**PFIZER INC AND SUBSIDIARY COMPANIES RECONCILIATION FROM REPORTED  
PHARMACEUTICAL REVENUES TO TOTAL  
IN-LINE AND NEW PRODUCTS(1) PHARMACEUTICAL REVENUES**

(UNAUDITED) (millions of dollars) Worldwide Second Quarter  
% Incr.

/

(Decr.)

Six Months  
% Incr.

/

(Decr.)

2008 2007 2008 2007 Total reported Pharmaceutical revenues \$ 11,053 \$  
10,105 9 \$ 21,957 \$ 21,686 1 Norvasc 627 642 (2) 1,140 1,711 (33 )  
Camptosar 137 241 (43 ) 329 470 (30 ) Zyrtec/Zyrtec D 8 385 (98 )  
125 846 (85 ) Total in-line products and new products(1)  
Pharmaceutical revenues \$ 10,281 \$ 8,837 16 \$ 20,363 \$ 18,659 9

U.S. Second Quarter

% Incr.

/

(Decr.)

Six Months

% Incr.

/

(Decr.)

2008	2007	2008	2007	Total reported Pharmaceutical revenues	\$ 4,382	\$
4,467	(2)	\$ 9,523	\$ 10,935	(13) Norvasc	42	18 132 37 529 (93)
Camptosar	6	130	(96)	89 260 (66)	Zyrtec/Zyrtec D	8 385 (98) 125
846	(85)	Total in-line products and new products(1)				

Pharmaceutical revenues \$ 4,326 \$ 3,934 10 \$ 9,272 \$ 9,300 -

International Second Quarter

% Incr

/

(Decr.)

Six Months

% Incr.

/

(Decr.)

2008	2007	2008	2007	Total reported Pharmaceutical revenues	\$ 6,671	\$
5,638	18	\$ 12,434	\$ 10,751	16 Norvasc	585	624 (6) 1,103 1,182 (7)
Camptosar	131	111	19	240 210 15	Zyrtec/Zyrtec D	- - - - -
Total in-line products and new products(1)				Pharmaceutical revenues		

\$ 5,955 \$ 4,903 21 \$ 11,091 \$ 9,359 19 Certain amounts and percentages may reflect rounding adjustments.

(1) Total in-line and new products Pharmaceutical revenues, which exclude the revenues of major products that have lost exclusivity in the U.S. since the beginning of 2007, is an alternative view of our Pharmaceutical revenues, and we believe that investors' understanding of Pharmaceutical revenues is enhanced by disclosing this performance measure. Norvasc lost its U.S. exclusivity in March 2007 and Camptosar lost its U.S.

exclusivity in February 2008, and as is typical in the pharmaceutical industry, this has resulted in a dramatic decline in revenues due to generic competition. Zyrtec/Zyrtec D lost its U.S. exclusivity in January 2008 and we ceased marketing the product in late January 2008. We believe that excluding the impact of these products assists the reader in understanding the underlying strength of the balance of our diverse Pharmaceutical product portfolio in 2008. Because of its non-standardized definition, this total in-line and new products Pharmaceutical revenues measure has limitations as it may not be comparable with the calculation of similar measures of other companies. This additional revenue measure is not, and should not be viewed as, a substitute for the U.S. GAAP comparison of Pharmaceutical revenues.

(2) Total in-line and new products Pharmaceutical international revenues reflect a favorable impact in the second quarter and first six months of 2008 due primarily to changes in foreign exchange rates.

## **PFIZER INC**

### **SUPPLEMENTAL INFORMATION**

#### **1) Impact of Foreign Exchange on Revenues**

The weakening of the U.S. dollar relative to other currencies, primarily the euro, Japanese yen and Canadian dollar, favorably impacted our revenues by approximately \$800 million, or 7%, in second-quarter 2008, compared to the same period in 2007, and by approximately \$1.4 billion, or 6%, in the first six months of 2008, compared to the same period in 2007.

#### **2) Change in Cost of Sales**

Reported cost of sales increased 9% in second-quarter 2008, compared to the same period in 2007. The increase primarily reflects the unfavorable impact of foreign exchange and higher implementation costs associated with our cost-reduction initiatives, partially offset by the savings impact of our cost-reduction initiatives.

Reported cost of sales included implementation charges related to our cost-reduction initiatives of \$210 million for the second quarter of 2008, \$348 million for the six months ended June 29, 2008, \$170 million for the second quarter of 2007, and \$264 million for the six months ended July 1, 2007.

Reported cost of sales also included \$45 million for the second quarter of 2008, \$93 million for the six months ended June 29, 2008, \$45 million for the second quarter of 2007, and \$80 million for the six months ended July 1, 2007, related to business-transition activities associated with the sale of our Consumer Healthcare business, completed in December 2006. This continuing activity is transitional in nature and generally results from agreements that seek to facilitate the orderly transfer of operations of our former Consumer Healthcare business to the new owner.

Reported cost of sales as a percentage of revenues of 18.9% in second-quarter 2008 was comparable to second-quarter 2007, reflecting the favorable impact of our cost-reduction initiatives, offset by higher 2008 implementation costs associated with our cost-reduction initiatives and the impact of foreign exchange.

### **3) Change in Selling, Informational & Administrative (SI&A) Expenses and Research & Development (R&D) Expenses**

Reported SI&A expenses in second-quarter 2008 increased 1%, and in the six months ended June 29, 2008, increased 2%, compared to the same periods in 2007, reflecting the unfavorable impact of foreign exchange, as well as the impact of higher 2008 implementation costs associated with our cost-reduction initiatives, partially offset by savings associated with our cost-reduction initiatives.

Reported SI&A expenses included implementation charges related to our cost-reduction initiatives of \$100 million for second-quarter 2008, \$175 million for the six months ended June 29, 2008, \$79 million for second-quarter 2007, and \$128 million for the six months ended July 1, 2007.

Reported R&D expenses, excluding acquisition-related in-process research and development charges (IPR&D), decreased 9% in second-quarter 2008, and decreased 2% in the six months ended June 29, 2008, compared to the same periods in 2007. The decreases are primarily due to the non-recurrence of the one-time 2007 payment to Bristol-Myers Squibb Company in connection with our collaboration to develop and commercialize apixaban, in addition to the realization of savings associated with our cost-reduction initiatives, partially offset by higher R&D spending related to our new collaboration agreements, as well as the unfavorable impact of foreign exchange.

Reported R&D expenses included implementation charges related to our cost-reduction initiatives of \$94 million for second-quarter 2008, \$240 million for the six months ended June 29, 2008, \$131 million for second-quarter 2007, and \$162 million for the six months ended July 1, 2007.



Other, Net

(14 ) (88 ) (58 ) (142 )

Other (Income)/Deductions-Net

\$ (167 ) \$ (487 ) \$ (500 ) \$ (889 )

\*Certain prior period amounts were reclassified to conform to the current period presentation.

(a) The decrease in net interest income in second-quarter and first six months of 2008, compared to the same periods in 2007, was due primarily to lower net financial assets and lower interest rates.

## 5) Effective Tax Rate

The effective tax rate on reported *Income from continuing operations before provision for taxes on income and minority interests* for second-quarter 2008 was 0.9% compared to 16.8% in second-quarter 2007, and in the first six months of 2008 was 12.4% compared to 16.9% in the first six months of 2007, reflecting tax benefits in the second quarter of 2008 of \$305 million related to favorable tax settlements for multiple tax years and \$426 million related to the sale of one of our biopharmaceutical companies (Esperion Therapeutic Inc.).

The effective tax rate on adjusted income<sup>1</sup> was 20.0% in second-quarter 2008, 21.0% in the first six months of 2008, 22.2% in second-quarter 2007, and 21.9% in the first six months of 2007. The lower rates on adjusted income(1) in 2008 reflect the \$305 million in tax benefits related to the resolution of tax issues noted above.

## 6) Reconciliation of 2008 Adjusted Income(1) and Adjusted Diluted EPS(1) Guidance to 2008 Reported Net Income and Reported Diluted EPS Guidance

Full-Year 2008 Guidance (\$ billions, except per-share amounts) Net Income(a)  
Diluted EPS(a)

Income/(Expense)

Adjusted Income/Diluted EPS(1) Guidance

~\$15.8 - \$16.6 ~\$2.35 - \$2.45 Purchase Accounting Impacts, Net of Tax: Business  
Development Transactions Completed as of 12/31/07 (2.1) (0.31) Business Development



Transactions Completed from 1/1/08 through 6/29/08 (0.5) (0.08) Costs Related to Cost-Reduction Initiatives, Net of Tax (1.6 - 1.9) (0.24 - 0.29) Tax Benefits Related to Sale of Esperion 0.4 0.06

Reported Net Income/Diluted EPS Guidance

~\$11.7 - \$12.8 ~\$1.73 - \$1.88

(a) Guidance in the table above excludes the effects of business development transactions not completed as of June 29, 2008.

While certain components of our 2008 reported guidance for net income and diluted EPS have been revised, the reported net income and diluted EPS expectation of \$11.7 billion - \$12.8 billion and \$1.73 - \$1.88 remains unchanged.

Our guidance excludes the impact of pending or prospective business development activity. During the second quarter of 2008, the net income and diluted EPS impact associated with 2008 completed business development transactions increased from \$0.3 billion and \$0.05 to \$0.5 billion and \$0.08, due to the recognition of IPR&D associated with our acquisitions of Serenex, Inc. and Encysive Pharmaceuticals Inc. in the second quarter of 2008. During the second quarter of 2008, the net income and diluted EPS effects of our cost-reduction initiatives have been revised from \$1.4 billion - \$1.7 billion and \$0.21 - \$0.26 to \$1.6 billion - \$1.9 billion and \$0.24 - \$0.29. The increase is principally driven by costs associated with site closures that were previously forecast to be recorded in 2009 that are now forecast to be incurred in 2008. These items are offset by tax benefits related to the sale of Esperion in the second quarter of 2008, which favorably impact net income and diluted EPS by \$0.4 billion and \$0.06.

(1) "Adjusted income" and "adjusted diluted earnings per share (EPS)" are defined as reported net income and reported diluted EPS excluding purchase-accounting adjustments, acquisition-related costs, discontinued operations and certain significant items. As described under *Adjusted Income* in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of Pfizer's Form 10-Q for the quarterly period ended March 30, 2008, management uses adjusted income, among other factors, to set performance goals and to measure the performance of the overall company. We believe that investors' understanding of our performance is enhanced by disclosing this measure. The adjusted income and adjusted diluted EPS measures are not, and should not be viewed as, substitutes for U.S. GAAP net income and diluted EPS.

*DISCLOSURE NOTICE: The information contained in this earnings release and the attachments is as of July 23, 2008. The Company assumes no obligation to update any forward-looking statements contained in this earnings release or the attachments as a result of new information or future events or developments.*

*This earnings release and the attachments contain forward-looking information about the Company's financial results and estimates, business plans and prospects, in-line products and product candidates that involve substantial risks and uncertainties. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," "target," "forecast" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business plans and prospects. Among the factors that could cause actual results to differ materially are the following: the success of research and development activities; decisions by regulatory authorities regarding whether and when to approve our drug applications as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of our products; the speed with which regulatory authorizations, pricing approvals and product launches may be achieved; the success of external business development activities; competitive developments, including with respect to competitor drugs and drug candidates that treat diseases and conditions similar to those treated by our in-line drugs and drug candidates; the ability to successfully market both new and existing products domestically and internationally; difficulties or delays in manufacturing; trade buying patterns; the ability to meet generic and branded competition after the loss of patent protection for our products and competitor products; the impact of existing and future legislation and regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment; U.S. legislation or regulatory action affecting, among other things, pharmaceutical product pricing, reimbursement or access, including under Medicaid and Medicare, the importation of prescription drugs from outside the U.S. at prices that are regulated by governments of various foreign countries, direct-to-consumer advertising and interactions with healthcare professionals and the involuntary approval of prescription medicines for over-the-counter use; the impact of the Medicare Prescription Drug, Improvement and Modernization Act of 2003; legislation or regulatory action in markets outside the U.S. affecting pharmaceutical product pricing, reimbursement or access; contingencies related to actual or alleged environmental contamination; claims and concerns that may arise regarding the safety or efficacy of in-line products and product candidates; significant breakdown, infiltration or interruption of our information technology systems and infrastructure; legal defense costs, insurance expenses, settlement costs and the risk of an adverse decision or settlement related to product*

*liability, patent protection, governmental investigations, ongoing efforts to explore various means for resolving asbestos litigation, and other legal proceedings; the Company's ability to protect its patents and other intellectual property both domestically and internationally; interest rate and foreign currency exchange rate fluctuations; governmental laws and regulations affecting domestic and foreign operations, including tax obligations; changes in generally accepted accounting principles; uncertainties related to general economic, political, business, industry, regulatory and market conditions; any changes in business, political and economic conditions due to the threat of terrorist activity in the U.S. and other parts of the world, and related U.S. military action overseas; growth in costs and expenses; changes in our product, segment and geographic mix; and the impact of acquisitions, divestitures, restructurings, product withdrawals and other unusual items, including our ability to realize the projected benefits of our cost-reduction initiatives. A further list and description of risks, uncertainties, and other matters can be found in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2007, and in its reports on Forms 10-Q and 8-K.*

*This earnings release may include discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data.*

Pfizer IncMediaShreya Jani, 212-733-4889orInvestorsSuzanne Harnett, 212-733-8009Jennifer Davis, 212-733-0717